$ATAI Life Sciences(ATAI.US)$ atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a atai Life Sciences has provided an update on Beckley Psytech's Phase 1/2a trial of ELE-101 for Major Depressive Disorder (MDD). ELE-101 is a synthetic psilocin formulation designed for a consistent and shorter treatment duration of approximately two hours. The Phas...
$ATAI Life Sciences(ATAI.US)$在古老的重要关键水平上形成的下降三角形和正向分歧使我们相信看涨情绪。这些领域的交易量似乎很大,但交易量不足。斐波那契回撤似乎表明在1.72处出现挫折,但可能会在1.42-1.45美元出现逆转...对波动率增加和交易 “期权” 的预期表明市场情绪看涨。不会...
ATAI Life Sciences股票讨论
https://www.fda.gov/news-events/press-announcements/fda-issues-first-draft-guidance-clinical-trials-psychedelic-drugs
你应该退房 $ATAI Life Sciences(ATAI.US)$ 也是。😉
$ATAI Life Sciences(ATAI.US)$看起来也不错!看到他们的药物取得的进步会很有趣。尤其是在约翰·霍普金斯大学进行类似研究的时候。
$ATAI Life Sciences(ATAI.US)$看起来也不错!看到他们的药物取得的进步会很有趣。尤其是在约翰·霍普金斯大学进行类似研究的时候。
$ATAI Life Sciences(ATAI.US)$看起来也很不错!
4 分钟前,美国东部时间上午 7:00
通过环球新闻专线
• ELE-101 是一种受专利保护的迷幻药合成配方,旨在以更一致、更可控和更短的治疗模式提供迷幻药的治疗功效,约为两小时...
atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a
atai Life Sciences has provided an update on Beckley Psytech's Phase 1/2a trial of ELE-101 for Major Depressive Disorder (MDD). ELE-101 is a synthetic psilocin formulation designed for a consistent and shorter treatment duration of approximately two hours. The Phas...
暂无评论